{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:07:57Z","timestamp":1761541677187,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T00:00:00Z","timestamp":1675468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chungbuk National University Korea National University Development Project","award":["2020"],"award-info":[{"award-number":["2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Even though low-molecular-weight heparin (LMWH), including dalteparin, has a critical role in portal vein thrombosis (PVT) treatment in liver cirrhosis (LC) patients, the predictive factors and the proper dose of dalteparin for PVT treatment and relapse have not yet been investigated. Materials and Methods: This retrospective study evaluated the records of LC patients receiving dalteparin from July 2013 to June 2019. The odds ratio (OR) and adjusted OR were calculated from univariate and multivariable analyses, respectively. Results: Among data from 121 patients, the overall recanalization rate of all patients was 66.1% (80 patients). No history of variceal bleeding (OR 4.6, 95% CI: 1.88\u201311.43) and the case of newly developed thrombus before dalteparin treatment (OR 3.2, 95% CI: 1.24\u20138.08) were predictive factors associated with increased treatment response. Relapse of PVT occurred in 32 out of 80 patients (40%) who showed a recanalization. The risk of relapse was 3.1\u20133.9 times higher in those who took more than three months or more than six months from the diagnosis of PVT to dalteparin treatment compared to those who took less than these durations, respectively. In the dosing regimen, patients with the kg-based dosing regimen showed 2.6 times better response than those with the fixed dosing regimen. However, no difference in bleeding complications was observed. Conclusion: In the dosing regimen, the kg-based regimen that was the same as the venous thromboembolism regimen was a better option for the efficacy and safety of dalteparin therapy. Additionally, when treating PVT in LC patients, careful monitoring is recommended for patients with predictive factors for treatment response and relapse of PVT.<\/jats:p>","DOI":"10.3390\/medicina59020292","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T02:57:32Z","timestamp":1675652252000},"page":"292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients"],"prefix":"10.3390","volume":"59","author":[{"given":"Ji Min","family":"Han","sequence":"first","affiliation":[{"name":"College of Pharmacy, Chungbuk National University, Cheongju 28160, Republic of Korea"},{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"},{"name":"Cancer Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Yun","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Sook","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Seoul National University Hospital, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0315-2080","authenticated-orcid":false,"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"},{"name":"Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"},{"name":"Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"},{"name":"Liver Research Institute, College of Medicine, Seoul National University, Seoul 03080, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-2563","authenticated-orcid":false,"given":"Hye Sun","family":"Gwak","sequence":"additional","affiliation":[{"name":"College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: Results of a longitudinal study","volume":"61","author":"Nery","year":"2015","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.14121","article-title":"Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study","volume":"39","author":"Ferreira","year":"2019","journal-title":"Liver Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.17998\/jlc.15.1.57","article-title":"3 Cases of Portal Vein Thrombosis in Hepatocellular Carcinoma and Liver Cirrhosis Treated with Anticoagulation","volume":"15","author":"Ahn","year":"2015","journal-title":"J. Liver Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: Evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMra1011170","article-title":"The coagulopathy of chronic liver disease","volume":"365","author":"Tripodi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2016). EASL Clinical Practice Guidelines: Vascular diseases of the liver. J. Hepatol., 64, 179\u2013202.","DOI":"10.1016\/j.jhep.2015.07.040"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis","volume":"54","author":"Koh","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1007\/s10620-020-06695-4","article-title":"Safety, efficacy, and long-term outcomes of anticoagulation in cirrhosis portal vein thrombosis","volume":"66","author":"Naymagon","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.jvir.2013.08.018","article-title":"Portal vein thrombosis after partial splenic embolization in liver cirrhosis: Efficacy of anticoagulation and long-term follow-up","volume":"24","author":"Cai","year":"2013","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/intqhc\/mzy177","article-title":"Anticoagulant medication errors in hospitals and primary care: A cross-sectional study","volume":"31","author":"Dreijer","year":"2019","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cld.2008.09.009","article-title":"International normalized ratio of prothrombin time in the model for end-stage liver disease score: An unreliable measure","volume":"13","author":"Arjal","year":"2009","journal-title":"Clin. Liver Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4254\/wjh.v13.i7.731","article-title":"Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis","volume":"13","author":"Pfisterer","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1572-0241.2007.01481.x","article-title":"Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis","volume":"102","author":"Sanyal","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3350\/cmh.2020.0022","article-title":"Managing liver cirrhosis complications: Overview of esophageal and gastric varices","volume":"26","author":"Lesmana","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"E1283","DOI":"10.1055\/a-0684-9638","article-title":"Recurrent esophagogastric variceal bleeding due to portal vein thrombosis caused by protein S deficiency","volume":"6","author":"Zhou","year":"2018","journal-title":"Endosc. Int. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cld.679","article-title":"Evaluation and management of acute and chronic portal vein thrombosis in patients with cirrhosis","volume":"10","author":"Young","year":"2017","journal-title":"Clin. Liver Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2018.01.032","article-title":"Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications","volume":"163","author":"Kwon","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_20","first-page":"776","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin","volume":"10","author":"Delgado","year":"2012","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"Cui","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am. J. Gastoenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1177\/1076029616675970","article-title":"Reversal of anticoagulation and management of bleeding in patients on anticoagulants","volume":"23","author":"Dhakal","year":"2017","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11239-019-01949-z","article-title":"The role of anticoagulation in pylephlebitis: A retrospective examination of characteristics and outcomes","volume":"49","author":"Naymagon","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jevtic, D., Gavrancic, T., Pantic, I., Nordin, T., Nordstrom, C.W., Antic, M., Pantic, N., Kaljevic, M., Joksimovic, B., and Jovanovic, M. (2022). Suppurative thrombosis of the portal vein (Pylphlebitis): A systematic review of literature. J. Clin. Med., 11.","DOI":"10.3390\/jcm11174992"},{"key":"ref_26","first-page":"804","article-title":"Pylephlebitis: An overview of non-cirrhotic cases and factors related to outcome. Scand","volume":"42","author":"Kanellopoulou","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1007\/s11605-015-2875-3","article-title":"Pylephlebitis: A Review of 95 Cases","volume":"20","author":"Choudhry","year":"2016","journal-title":"J. Gastrointest. Surg."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:24:03Z","timestamp":1760120643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/2\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,4]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["medicina59020292"],"URL":"https:\/\/doi.org\/10.3390\/medicina59020292","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2023,2,4]]}}}